Tirzepatide
US$ 25.14
glp-1 agonist weight loss mechanism and Anesthesia: Considerations and Cautions for CRNAs GLP-1RAs Reduce External Eating Behavior
Description
DOI: 10.3390/nu15224809
Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G, Liu F, Miller C, Tota LM, Zhou G, Zhang X, Sountis MM, Santoprete A, Capito E, Chicchi GG, Thornberry N, Bianchi E, Pessi A, Marsh DJ, Sinha RR
A key double-blind, placebo-controlled phase II study conducted over 72 weeks recruited 320 individuals with histologically confirmed NASH and liver fibrosis classified as stage F1 to F3
[2] Salvador, J
The study made headlines at the 2026 American Society of Clinical Oncology (ASCO) annual meeting in June
13, 14 However, serious problems are rare
